Page last updated: 2024-11-02

moxonidine and Ventricular Dysfunction, Left

moxonidine has been researched along with Ventricular Dysfunction, Left in 3 studies

moxonidine: structure given in first source

Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.

Research Excerpts

ExcerptRelevanceReference
"A total of 268 patients with chronic heart failure in NYHA functional class II to IV on optimal standard therapy were randomized to placebo or 1 of 5 doses of moxonidine SR: 0."9.10Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Dargie, H; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2002)
"Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure."7.79Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. ( Hirooka, Y; Honda, N; Ito, K; Kishi, T; Matsukawa, R; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K, 2013)
"A total of 268 patients with chronic heart failure in NYHA functional class II to IV on optimal standard therapy were randomized to placebo or 1 of 5 doses of moxonidine SR: 0."5.10Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Dargie, H; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2002)
"Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure."3.79Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. ( Hirooka, Y; Honda, N; Ito, K; Kishi, T; Matsukawa, R; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K, 2013)
" This study evaluates the effects of moxonidine and metoprolol on cardiac hemodynamics and survival in ADR-induced left ventricular dysfunction (total dose of 20 mg/kg in a 4-week regimen)."3.72Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats. ( Bellmont, S; Christen, MO; La Roche, B; Monassier, L; Thomas, L, 2004)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Honda, N1
Hirooka, Y1
Ito, K1
Matsukawa, R1
Shinohara, K1
Kishi, T1
Yasukawa, K1
Utsumi, H1
Sunagawa, K1
Thomas, L1
Bellmont, S1
Christen, MO1
La Roche, B1
Monassier, L1
Swedberg, K1
Bristow, MR1
Cohn, JN1
Dargie, H1
Straub, M1
Wiltse, C1
Wright, TJ1

Trials

1 trial available for moxonidine and Ventricular Dysfunction, Left

ArticleYear
Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
    Circulation, 2002, Apr-16, Volume: 105, Issue:15

    Topics: Blood Pressure; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doub

2002

Other Studies

2 other studies available for moxonidine and Ventricular Dysfunction, Left

ArticleYear
Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure.
    Journal of hypertension, 2013, Volume: 31, Issue:11

    Topics: Animals; Antihypertensive Agents; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Imidaz

2013
Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats.
    Fundamental & clinical pharmacology, 2004, Volume: 18, Issue:6

    Topics: Adrenergic beta-Antagonists; Animals; Antibiotics, Antineoplastic; Dose-Response Relationship, Drug;

2004